Edgewise Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Edgewise Therapeutics has a total shareholder equity of $488.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $511.3M and $22.4M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$492.54m |
| Equity | US$488.88m |
| Total liabilities | US$22.41m |
| Total assets | US$511.28m |
Recent financial health updates
Here's Why We're Not Too Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Situation
Nov 26
We Think Edgewise Therapeutics (NASDAQ:EWTX) Can Afford To Drive Business Growth
Aug 12We're Not Very Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Rate
May 10Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth
Dec 07Edgewise Therapeutics (NASDAQ:EWTX) Is In A Good Position To Deliver On Growth Plans
Aug 16Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth
Apr 28Recent updates
Edgewise: Remains A Buy After Latest Becker Muscular Dystrophy Data
Dec 31Here's Why We're Not Too Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Situation
Nov 26Edgewise: Stock Is Bouncing On Heart Disease Drug Data, Albeit From Just 7 Patients (Rating Upgrade)
Sep 19We Think Edgewise Therapeutics (NASDAQ:EWTX) Can Afford To Drive Business Growth
Aug 12Edgewise Therapeutics: Strong Open Label Data Makes For A Bullish Signal
Aug 05Edgewise: Intriguing Drug Candidate, But Consider Selling After Recent Run
May 10We're Not Very Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Rate
May 10Edgewise Therapeutics: Behind The Massive Rally
Feb 18Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth
Dec 07Edgewise Therapeutics (NASDAQ:EWTX) Is In A Good Position To Deliver On Growth Plans
Aug 16Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth
Apr 28We Think Edgewise Therapeutics (NASDAQ:EWTX) Can Afford To Drive Business Growth
Jan 13Edgewise Therapeutics proposes $100M stock offering plan
Sep 13Edgewise Therapeutics GAAP EPS of -$0.32 beats by $0.02
Aug 04Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth
Aug 02We're Hopeful That Edgewise Therapeutics (NASDAQ:EWTX) Will Use Its Cash Wisely
Mar 24We're Hopeful That Edgewise Therapeutics (NASDAQ:EWTX) Will Use Its Cash Wisely
Nov 23Edgewise Therapeutics names new chief medical officer
Apr 27Financial Position Analysis
Short Term Liabilities: EWTX's short term assets ($499.4M) exceed its short term liabilities ($19.0M).
Long Term Liabilities: EWTX's short term assets ($499.4M) exceed its long term liabilities ($3.4M).
Debt to Equity History and Analysis
Debt Level: EWTX is debt free.
Reducing Debt: EWTX had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EWTX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: EWTX has sufficient cash runway for 2.7 years if free cash flow continues to reduce at historical rates of 42.9% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/06 21:06 |
| End of Day Share Price | 2025/02/06 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Edgewise Therapeutics, Inc. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Cory Kasimov | Evercore ISI |
| Madhu Kumar | Goldman Sachs |
| Paul Choi | Goldman Sachs |